Jefferies (NYSE:JEF) analyst Owen Bennett maintained a Buy rating on Trulieve Cannabis (OTC:TCNNF) on Sunday, setting a price target of C$65, which is approximately 73.12% above the present share price of $29.97.
Bennett expects Trulieve Cannabis to post earnings per share (EPS) of $0.25 for the third quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Trulieve Cannabis, with an average price target of $62.01.
The analysts price targets range from a high of $77.42 to a low of $50.5.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $193.82 million and a net profit of $72.56 million. The company's market cap is $3.6 billion.
According to TipRanks.com, Jefferies analyst Owen Bennett is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -3.1% and a 37.41% success rate.
Trulieve Cannabis Corp. engages in the provision of medical cannabis products. The firm cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. Its products include smokable flower, inhalation, oral, sublingual, topical, inter-nasal, and concentrates. The company was founded on September 21, 2018 and is headquartered in Quincy, FL.